News | June 14, 2024

COGENT BIOSCIENCES ANNOUNCES ADDITIONAL CLINICAL DATA FROM PART 1 OF ITS ONGOING SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) Patients treated with 100 mg bezuclastinib showed substantial reduction in their most...